Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus-An effect probably mediated by direct platelet PPARγ activation

Atherosclerosis

Volumn 197, Issue 2, 2008, Pages 718-724

  Khanolkar, M P ^a   Morris, R H K ^b   Thomas, A W ^b   Bolusani, H ^a   Roberts, A W ^a   Geen, J ^c   Jackson, S K ^d   Evans, L M ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b CARDIFF METROPOLITAN UNIVERSITY   (United Kingdom)

^c PRINCE CHARLES HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Platelets; Rosiglitazone; Type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLICLAZIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PLATELETS; CD40 LIGAND; DIABETES MELLITUS, TYPE 2; FEMALE; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLATELET AGGREGATION; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 40949098983     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.07.020     Document Type: Article

References (36)

1. Malmberg K., Yusuf S., Gerstein H.C., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102 (2000) 1014-1019
2. Fuster V., Badimon L., Badimon J.J., and Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326 (1992) 310-318
3. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
4. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., and Patterson J.K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 263 (1990) 2893-2898
5. Ferroni P., Basili S., Falco A., and Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2 (2004) 1282-1291
6. Grant P.J. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 29 (2003) 6S44-6S52
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
8. Ibrahimi A., Teboul L., Gaillard D., et al. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol 46 (1994) 1070-1076
9. Uwaifo G.I., and Ratner R.E. The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. Am J Med 115 Suppl. 8A (2003) 12S-19S
10. Da Ros R., Assaloni R., and Ceriello A. The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabetes Med 21 (2004) 1249-1252
11. Fonseca V., Jawa A., and Asnani S. The PROACTIVE study: the glass is half full. J Clin Endocrinol Metab (2005)
12. Akbiyik F., Ray D.M., Gettings K.F., Blumberg N., Francis C.W., and Phipps R.P. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104 (2004) 1361-1368
13. Sidhu J.S., Cowan D., Tooze J.A., and Kaski J.C. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 147 (2004) e25
14. Ishiwata S., Tukada T., Nakanishi S., Nishiyama S., and Seki A. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 133 (1997) 387-392
15. Choi D., Kim S.K., Choi S.H., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27 (2004) 2654-2660
16. Siluk D., Kaliszan R., Haber P., Petrusewicz J., Brzozowski Z., and Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia 45 (2002) 1034-1037
17. Wasowicz W., Neve J., and Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. Clin Chem 39 (1993) 2522-2526
18. +]i elevation induced by arachidonic acid. Biochem Pharmacol 49 (1995) 1735-1739
19. Okouchi M., Okayama N., Omi H., et al. The antidiabetic agent, gliclazide, reduces high insulin-enhanced neutrophil-transendothelial migration through direct effects on the endothelium. Diabetes Metab Res Rev 20 (2004) 232-238
20. Vinik A.I., Erbas T., Park T.S., Nolan R., and Pittenger G.L. Platelet dysfunction in type 2 diabetes. Diabetes Care 24 (2001) 1476-1485
21. Falcon C., Pfliegler G., Deckmyn H., and Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun 157 (1988) 1190-1196
22. Kerr R., Stirling D., and Ludlam C.A. Interleukin 6 and haemostasis. Br J Haematol 115 (2001) 3-12
23. Ricote M., Huang J., Fajas L., et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95 (1998) 7614-7619
24. Cabrero A., Laguna J.C., and Vazquez M. Peroxisome proliferator-activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy 1 (2002) 243-248
25. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 61 (2004) 498-511
26. De Cristofaro R., Rocca B., Vitacolonna E., et al. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost 1 (2003) 250-256
27. Davi G., Ciabattoni G., Consoli A., et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99 (1999) 224-229
28. Chung B.H., Segrest J.P., Ray M.J., et al. Single vertical spin density gradient ultracentrifugation. Methods Enzymol 128 (1986) 181-209
29. Valgimigli M., Merli E., Malagutti P., et al. Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Arch Biochem Biophys 420 (2003) 255-261
30. Ishizuka T., Itaya S., Wada H., et al. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 47 (1998) 1494-1500
31. Radomski M.W., Palmer R.M., and Moncada S. An l-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87 (1990) 5193-5197
32. Signorello M.G., Giovine M., Pascale R., et al. Impaired l-arginine uptake in platelets from type-2 diabetic patients. Biotechnol Appl Biochem 34 (2001) 19-23
33. Palmer R.M., and Moncada S. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun 158 (1989) 348-352
34. Li D., Chen K., Sinha N., et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 65 (2005) 907-912
35. Calnek D.S., Mazzella L., Roser S., Roman J., and Hart C.M. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23 (2003) 52-57
36. Cho D.H., Choi Y.J., Jo S.A., and Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem 279 (2004) 2499-2506